Trial Profile
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms TITRATION
- Sponsors Biogen
- 24 Dec 2021 This trial has been completed in Czech Republic (Date of the global end of the trial : 08 Jan 2016), according to European Clinical Trials Database record.
- 09 Jun 2017 This trial has been completed in Germany (on 2015-11-04), according to European Clinical Trials Database
- 20 Nov 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.